Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups.

Spivey CA, Qiao Y, Wang J, Shih YT, Wan JY, Dagogo-Jack S, Cushman WC, Hines LE, Chisholm-Burns MA.

J Am Geriatr Soc. 2019 Jan 23. doi: 10.1111/jgs.15754. [Epub ahead of print]

PMID:
30674080
2.

Awareness of Prediabetes Status and Subsequent Health Behavior, Body Weight, and Blood Glucose Levels.

Owei I, Umekwe N, Ceesay F, Dagogo-Jack S.

J Am Board Fam Med. 2019 Jan-Feb;32(1):20-27. doi: 10.3122/jabfm.2019.01.180242.

3.

Genetic Ancestry Markers and Difference in A1c Between African American and White in the Diabetes Prevention Program.

Hivert MF, Christophi CA, Jablonski KA, Edelstein SL, Kahn SE, Golden SH, Dagogo-Jack S, Mather KJ, Luchsinger JA, Caballero AE, Barrett-Connor E, Knowler WC, Florez JC, Herman WH.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):328-336. doi: 10.1210/jc.2018-01416.

PMID:
30358859
4.

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators.

Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5.

5.

Physiology of Glycemic Recovery and Stabilization After Hyperinsulinemic Euglycemic Clamp in Healthy Subjects.

Owei I, Jain N, Jones D, Umekwe N, Dagogo-Jack S.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):4155-4162. doi: 10.1210/jc.2018-01569.

PMID:
30239760
6.

Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.

Qiao Y, Spivey CA, Wang J, Shih YT, Wan JY, Kuhle J, Dagogo-Jack S, Cushman WC, Chisholm-Burns MA.

Inquiry. 2018 Jan-Dec;55:46958018795749. doi: 10.1177/0046958018795749.

7.

Parental history of type 2 diabetes is associated with lower resting energy expenditure in normoglycemic subjects.

Nyenwe EA, Ogwo CC, Owei I, Wan JY, Dagogo-Jack S.

BMJ Open Diabetes Res Care. 2018 Jun 7;6(1):e000511. doi: 10.1136/bmjdrc-2018-000511. eCollection 2018.

8.

Ethnic Disparities in Endothelial Function and Its Cardiometabolic Correlates: The Pathobiology of Prediabetes in A Biracial Cohort Study.

Owei I, Umekwe N, Mohamed H, Ebenibo S, Wan J, Dagogo-Jack S.

Front Endocrinol (Lausanne). 2018 Mar 13;9:94. doi: 10.3389/fendo.2018.00094. eCollection 2018.

9.

Basal and Dynamic Leptin Secretion: Association with Cardiometabolic Risk and Body Weight Trajectories in African-Americans and European-Americans.

Ebenibo S, Edeoga C, Owei I, Dagogo-Jack S.

Front Endocrinol (Lausanne). 2018 Jan 26;9:12. doi: 10.3389/fendo.2018.00012. eCollection 2018.

10.

Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction.

Brannick B, Dagogo-Jack S.

Endocrinol Metab Clin North Am. 2018 Mar;47(1):33-50. doi: 10.1016/j.ecl.2017.10.001. Review.

PMID:
29407055
11.

Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.

Spivey CA, Wang J, Qiao Y, Shih YT, Wan JY, Kuhle J, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

J Manag Care Spec Pharm. 2018 Feb;24(2):97-107. doi: 10.18553/jmcp.2018.24.2.97.

12.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2018 Jan;24(1):91-120. doi: 10.4158/CS-2017-0153. Epub 2018 Jan 17.

PMID:
29368965
13.

Parental History of Type 2 Diabetes Abrogates Ethnic Disparities in Key Glucoregulatory Indices.

Nyenwe E, Owei I, Wan J, Dagogo-Jack S.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):514-522. doi: 10.1210/jc.2017-01895.

PMID:
29216357
14.

AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES.

Fonseca VA, Bloomgarden ZT, Dagogo-Jack S, Grunberger G, Einhorn D, Garber AJ, Handelsman Y, Hirsch IB, Umpierrez GE.

Endocr Pract. 2017 Nov;23(11):1345-1349. doi: 10.4158/EP-2017-0052.

PMID:
29190135
15.

Safety of Degludec versus Glargine in Type 2 Diabetes.

Ogunsakin AA, Jain N, Dagogo-Jack S.

N Engl J Med. 2017 Nov 16;377(20):1994. doi: 10.1056/NEJMc1712575. No abstract available.

PMID:
29143513
16.

Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.

Ogunsakin A, Solomon SS, Dagogo-Jack S.

N Engl J Med. 2017 Oct 5;377(14):e20. doi: 10.1056/NEJMc1709989. No abstract available.

PMID:
28980795
17.

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.

Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B.

Diabetes Obes Metab. 2018 Mar;20(3):530-540. doi: 10.1111/dom.13116. Epub 2017 Oct 23.

18.

Relationships between blood pressure and blood glucose among offspring of parents with type 2 diabetes: Prediction of incident dysglycemia in a biracial cohort.

Edeoga C, Owei I, Siwakoti K, Umekwe N, Ceesay F, Wan J, Dagogo-Jack S.

J Diabetes Complications. 2017 Nov;31(11):1580-1586. doi: 10.1016/j.jdiacomp.2017.07.019. Epub 2017 Aug 2.

PMID:
28890305
19.

Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort.

Owei I, Umekwe N, Provo C, Wan J, Dagogo-Jack S.

BMJ Open Diabetes Res Care. 2017 Jul 19;5(1):e000415. doi: 10.1136/bmjdrc-2017-000415. eCollection 2017.

20.

Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).

Perreault L, Pan Q, Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Mather KJ, Knowler WC; Diabetes Prevention Program Research Group.

Diabet Med. 2017 Dec;34(12):1747-1755. doi: 10.1111/dme.13453. Epub 2017 Sep 19.

21.

Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.

Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F.

Diabetes Obes Metab. 2018 Feb;20(2):409-418. doi: 10.1111/dom.13086. Epub 2017 Oct 5.

22.

Editorial: The continuum of dysglycemia: Predicting progression from prediabetes to type 2 diabetes.

Dagogo-Jack S.

J Diabetes Complications. 2017 Aug;31(8):1249-1251. doi: 10.1016/j.jdiacomp.2017.05.012. Epub 2017 May 27. No abstract available.

PMID:
28610946
23.

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048. No abstract available.

24.

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.

Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S.

Diabetes Obes Metab. 2017 May;19(5):721-728. doi: 10.1111/dom.12888. Epub 2017 Feb 22.

PMID:
28116776
25.

Combination of Recreational Soccer and Caloric Restricted Diet Reduces Markers of Protein Catabolism and Cardiovascular Risk in Patients with Type 2 Diabetes.

Vieira de Sousa M, Fukui R, Krustrup P, Dagogo-Jack S, Rossi da Silva ME.

J Nutr Health Aging. 2017;21(2):180-186. doi: 10.1007/s12603-015-0708-4.

PMID:
28112773
26.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS. Epub 2017 Jan 17.

PMID:
28095040
27.

Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.

Kum-Nji JS, Gosmanov AR, Steinberg H, Dagogo-Jack S.

J Diabetes Complications. 2017 Mar;31(3):611-614. doi: 10.1016/j.jdiacomp.2016.11.004. Epub 2016 Nov 9.

PMID:
27913012
28.

Replication of the Association of BDNF and MC4R Variants With Dietary Intake in the Diabetes Prevention Program.

McCaffery JM, Jablonski KA, Franks PW, Delahanty LM, Aroda V, Marrero D, Hamman RF, Horton ES, Dagogo-Jack S, Wylie-Rosett J, Barrett-Connor E, Kitabchi A, Knowler WC, Wing RR, Florez JC; Diabetes Prevention Program Research Group.

Psychosom Med. 2017 Feb/Mar;79(2):224-233. doi: 10.1097/PSY.0000000000000380.

29.

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798. Epub 2016 Jul 27.

30.

Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms.

Owei I, Umekwe N, Wan J, Dagogo-Jack S.

Exp Biol Med (Maywood). 2016 Nov;241(17):1961-1967. Epub 2016 Jul 17.

31.

Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications.

Brannick B, Wynn A, Dagogo-Jack S.

Exp Biol Med (Maywood). 2016 Jun;241(12):1323-31. doi: 10.1177/1535370216654227. Review.

32.

Diabetes Care in Nigeria.

Fasanmade OA, Dagogo-Jack S.

Ann Glob Health. 2015 Nov-Dec;81(6):821-9. doi: 10.1016/j.aogh.2015.12.012. Review.

33.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR.

Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.

PMID:
27082665
34.

Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study.

Jiang Y, Owei I, Wan J, Ebenibo S, Dagogo-Jack S.

BMJ Open Diabetes Res Care. 2016 Mar 17;4(1):e000194. doi: 10.1136/bmjdrc-2016-000194. eCollection 2016.

35.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE).

Endocr Pract. 2016 Jan;22(1):84-113. doi: 10.4158/EP151126.CS. No abstract available.

PMID:
26731084
36.

2015 Presidential Address: 75 Years of Battling Diabetes--Our Global Challenge.

Dagogo-Jack S.

Diabetes Care. 2016 Jan;39(1):3-9. doi: 10.2337/dc15-1818.

PMID:
26696655
37.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE).

Endocr Pract. 2015 Dec;21(12):1403-14. doi: 10.4158/EP151063.CS.

PMID:
26642101
39.

Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.

Wang J, Qiao Y, Shih YC, Jarrett-Jamison J, Spivey CA, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

J Manag Care Spec Pharm. 2015 Nov;21(11):993-1003.

40.

Dietary habits and leisure-time physical activity in relation to adiposity, dyslipidemia, and incident dysglycemia in the pathobiology of prediabetes in a biracial cohort study.

Boucher AB, Adesanya EA, Owei I, Gilles AK, Ebenibo S, Wan J, Edeoga C, Dagogo-Jack S.

Metabolism. 2015 Sep;64(9):1060-7. doi: 10.1016/j.metabol.2015.05.015. Epub 2015 Jun 6.

41.

AACE/ACE comprehensive diabetes management algorithm 2015.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH.

Endocr Pract. 2015 Apr;21(4):438-47. doi: 10.4158/EP15693.CS. Epub 2015 Apr 15. No abstract available.

PMID:
25877012
42.

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.

Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F.

Endocr Pract. 2015 Apr;21 Suppl 1:1-87. doi: 10.4158/EP15672.GL. No abstract available.

43.

Erratum to: Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.

Ibebuogu UN, Bolorunduro O, Giri S, Dagogo-Jack S, Smith BG, Kar S, Reed GL.

Am J Cardiovasc Drugs. 2015 Aug;15(4):287. doi: 10.1007/s40256-015-0118-3. No abstract available.

PMID:
25829095
44.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY.

Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F.

Endocr Pract. 2015 Apr;21(4):413-37. No abstract available.

PMID:
27408942
45.

Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.

Ibebuogu UN, Bolorunduro O, Giri S, Dagogo-Jack S, Smith BG, Kar S, Reed GL.

Am J Cardiovasc Drugs. 2015 Aug;15(4):275-85. doi: 10.1007/s40256-015-0113-8. Erratum in: Am J Cardiovasc Drugs. 2015 Aug;15(4):287.

PMID:
25782437
46.

Effects of medicare part d on disparity implications of medication therapy management eligibility criteria.

Wang J, Qiao Y, Shih YC, Jamison JJ, Spivey CA, Li L, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

Am Health Drug Benefits. 2014 Sep;7(6):346-58.

47.

Health Implications of the MTM Eligibility Criteria In The Affordable Care Act Across Racial And Ethnic Groups.

Wang J, Qiao Y, Shih YC, Jamison JJ, Spivey CA, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

Value Health. 2014 Nov;17(7):A789. doi: 10.1016/j.jval.2014.08.426. Epub 2014 Oct 26. No abstract available.

48.

American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease.

Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G; The Aace Obesity Scientific Committee.

Endocr Pract. 2014 Sep;20(9):977-89. doi: 10.4158/EP14280.PS. No abstract available.

49.

American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action.

Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, On Behalf Of The Aace Obesity Scientific Committee.

Endocr Pract. 2014 Sep;20(9):956-76. doi: 10.4158/EP14279.CS.

PMID:
25253226
50.

Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria.

Wang J, Qiao Y, Tina Shih YC, Spivey CA, Dagogo-Jack S, Wan JY, White-Means SI, Cushman WC, Chisholm-Burns MA.

J Pharm Health Serv Res. 2014 Jun;5(2):109-118.

Supplemental Content

Loading ...
Support Center